FDA Approves Dupilumab for COPD: 30% Exacerbation Reduction in BOREAS Trial

Executive Brief

News Report

The News: FDA approves dupilumab for COPD, showing significant efficacy in reducing exacerbations.
Clinical Win: This approval introduces a new treatment option for patients with type 2 inflammation in COPD.
Target Specialty: Pulmonology

Key Data at a Glance

Exacerbation Reduction: 30%
Patient Enrollment: 939
Event Rate Dupilumab: 19.7%
Event Rate Placebo: 28.2%

The FDA has approved dupilumab (Dupixent) for the treatment of chronic obstructive pulmonary disease (COPD) based on results from the BOREAS trial, which demonstrated a 30% reduction in moderate or severe exacerbations compared to placebo over 52 weeks (p<0.001) [1]. This approval marks a significant advancement in the management of COPD, particularly for patients with type 2 inflammation, a subgroup that has limited treatment options available [1]. The announcement was made on May 21, 2023, following the trial's presentation at the American Thoracic Society (ATS) conference [7].

Clinical Context

Chronic obstructive pulmonary disease (COPD) is a progressive lung disease characterized by persistent respiratory symptoms and airflow limitation. It is often associated with chronic inflammation in the airways and lungs, leading to exacerbations that significantly impact patients' quality of life and overall health. Current treatments primarily focus on bronchodilation and corticosteroids, but many patients remain symptomatic and experience frequent exacerbations despite maximal therapy. There is a particular need for new therapeutic options for patients with type 2 inflammation, as they often do not respond adequately to existing treatments. Dupilumab, a monoclonal antibody that inhibits interleukin-4 and interleukin-13 signaling, has shown promise in reducing inflammation and improving lung function in patients with asthma and atopic dermatitis. The BOREAS trial aimed to evaluate the efficacy and safety of dupilumab in patients with COPD and type 2 inflammation, providing critical data for its use in this population.

Key Findings

The BOREAS trial showed dupilumab reduced moderate or severe acute COPD exacerbations by 30% versus placebo (HR not provided; p<0.001) over 52 weeks [1].

The trial enrolled 939 patients with uncontrolled COPD and type 2 inflammation, defined by a blood eosinophil count of at least 300 cells per microliter [1].

Event rates: 19.7% of patients receiving dupilumab experienced exacerbations compared to 28.2% in the placebo group [1].

The primary endpoint was the reduction in moderate or severe acute exacerbations of COPD [1].

What This Means for Clinical Practice

Dupilumab is now indicated for patients with COPD who exhibit type 2 inflammation, as demonstrated in the BOREAS trial. This approval provides clinicians with a new option to manage exacerbations in a population that has historically faced challenges with existing therapies. The significant reduction in exacerbations and improvements in lung function and quality of life measures suggest that dupilumab can meaningfully impact patient care. Clinicians should consider evaluating eosinophil counts and other biomarkers of type 2 inflammation in their COPD patients to identify those who may benefit from dupilumab therapy. As this treatment becomes integrated into clinical practice, ongoing assessment of its long-term effects and cost-effectiveness will be essential to optimize patient outcomes and resource allocation in COPD management.

Clinical Perspective

Workflow: Clinicians should assess eosinophil levels in COPD patients to identify those who may benefit from dupilumab.

Economics: The introduction of dupilumab may impact healthcare costs associated with COPD exacerbations and hospitalizations.

Patient Outcomes: Improved management of COPD exacerbations can enhance patients' quality of life and reduce the burden of the disease.

Dr. Nikhil Chatterjee, Pulmonology

FDA Approves Dupilumab for COPD: 30% Exacerbation Reduction in BOREAS Trial

Executive Brief

Key Data at a Glance

Clinical Context

Key Findings

What This Means for Clinical Practice

Clinical Perspective

References

Get weekly drug updates for Pulmonology in your inbox.

Related Drug Updates

FDA Approves Tezepelumab for Severe Asthma: 52% Exacerbation Reduction in NAVIGATOR Trial

FDA Approves Depemokimab for Severe Asthma: New Eosinophilic Treatment Option

Severe Asthma Biologics: Mepolizumab, Benralizumab, Dupilumab, Tezepelumab, and Depemokimab Insights for 2025

Verified HCP Portal